Halozyme Therapeutics | HALO - Trade Creditors


Halozyme Therapeutics reported $20.9M in Trade Creditors for its fiscal quarter ending in December of 2025.





Trade Creditors Change Date
Acadia Pharmaceuticals USD 10.9M 10.84M Dec/2025
Agios Pharmaceuticals USD 18.36M 1.2M Dec/2025
Alnylam Pharmaceuticals USD 115.72M 1.87M Dec/2025
Amarin USD 36.71M 8M Sep/2025
Amgen USD 20.89B 1.25B Dec/2025
Baxter International USD 999M 46M Dec/2025
Cara Therapeutics USD 2.42M 2.42M Jun/2025
Cytokinetics USD 105.62M 83.53M Dec/2025
DBV Technologies USD 39.82M 972K Sep/2025
Eli Lilly USD 5.38B 1.12B Dec/2025
Esperion Therapeutics USD 77.51M 2.81M Sep/2025
Halozyme Therapeutics USD 20.9M 5.54M Dec/2025
Intrexon USD 4.85M 3.12M Jun/2024
Ionis Pharmaceuticals USD 14.33M 8.47M Sep/2025
MannKind USD 9.03M 1.76M Dec/2025
Minerva Neurosciences USD 945K 48K Sep/2025
Nektar Therapeutics USD 15.56M 1.28M Sep/2025
Pfizer USD 5.02B 142M Sep/2025
Rigel Pharmaceuticals USD 3.85M 3.44M Sep/2025
United Therapeutics USD 7.1M 460.9M Dec/2025
Vanda Pharmaceuticals USD 39.09M 33.28M Dec/2024